ReviewTreatment of lung infection in patients with cystic fibrosis: Current and future strategies☆,☆☆
Cited by (0)
- ☆
This document is the result of a European Consensus Conference which took place in Artimino, Tuscany, Italy, on April 27–29, 2012, involving various international experts on antibiotic therapy against microbial pathogens in cystic fibrosis patients, organized by the European Cystic Fibrosis Society, and sponsored by Aptalis, Bayer Schering Pharma, Chiesi, Forest Laboratories UK Ltd, Gilead Sciences, Inc., Insmed Incorporated, Novartis Pharma and Pari Pharma GmbH. The purpose of the conference was to develop a consensus document on current and future strategies for the treatment of lung disease in cystic fibrosis based on current evidence.
- ☆☆
Disclaimer. The views presented in this Correspondence are those of the authors and should not be understood or quoted as being made on behalf of the European Medicines Agency or its scientific Committees.